BUZZ-Biotech firm Protara tumbles on planned $75 mln equity raise
I'm PortAI, I can summarize articles.
Protara Therapeutics plans a $75 million equity raise, causing shares to drop 12% to $6.05. The funds will support the development of TARA-002 for bladder cancer and lymphatic malformations. With a market cap of $265 million, the offering is managed by JP Morgan, TD Cowen, and Piper Sandler. Despite the drop, TARA shares have gained 58% QTD and 30% YTD, with analysts bullish and a median price target of $25.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments